Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Humacyte Inc (HUMA)

Humacyte Inc (HUMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 184,592
  • Shares Outstanding, K 155,119
  • Annual Sales, $ 0 K
  • Annual Income, $ -148,700 K
  • EBIT $ -114 M
  • EBITDA $ -107 M
  • 60-Month Beta 1.64
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 145.98% ( +8.06%)
  • Historical Volatility 127.25%
  • IV Percentile 68%
  • IV Rank 36.23%
  • IV High 273.17% on 12/09/24
  • IV Low 73.71% on 02/20/25
  • Put/Call Vol Ratio 0.38
  • Today's Volume 2,177
  • Volume Avg (30-Day) 987
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 69,824
  • Open Int (30-Day) 67,741

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.19
  • Number of Estimates 1
  • High Estimate -0.19
  • Low Estimate -0.19
  • Prior Year -0.29
  • Growth Rate Est. (year over year) +34.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1800 +11.86%
on 05/09/25
1.7000 -22.35%
on 04/17/25
-0.2100 (-13.73%)
since 04/11/25
3-Month
1.1500 +14.78%
on 04/08/25
4.1400 -68.12%
on 02/14/25
-2.6400 (-66.67%)
since 02/12/25
52-Week
1.1500 +14.78%
on 04/08/25
9.9700 -86.76%
on 05/31/24
-3.3800 (-71.91%)
since 05/10/24

Most Recent Stories

More News
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025

HUMA : 1.3200 (+10.92%)
Humacyte Stock Continues Slide Despite Lower Than Expected Q4 Loss – But Retail Gets More Bullish

Fourth-quarter loss per share came in at $0.16, lower than the $0.24 in the corresponding period of 2023, and below the consensus estimate of $0.25, according to FinChat data.

HUMA : 1.3200 (+10.92%)
VTI : 287.27 (+3.35%)
IWM : 207.87 (+3.52%)
Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

HUMA : 1.3200 (+10.92%)
Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025

HUMA : 1.3200 (+10.92%)
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

HUMA : 1.3200 (+10.92%)
Humacyte, Inc. Announces Proposed Public Offering of Common Stock

HUMA : 1.3200 (+10.92%)
Durable Goods, Home Sales in U.S. Due Next Week

U.S. Monday Economic Lookahead S&P flash U.S. services PMI (March) S&P flash ...

CNM : 53.29 (+3.20%)
HUMA : 1.3200 (+10.92%)
MKC : 76.49 (+0.55%)
BRZE : 36.14 (+7.30%)
DLTR : 89.00 (+4.13%)
TMC : 3.14 (+0.96%)
EPAC : 45.51 (+4.89%)
DIV.TO : 2.95 (+1.03%)
KBH : 56.13 (+4.02%)
LULU : 304.20 (+8.73%)
CKPT : 4.16 (-0.24%)
KEI.TO : 8.39 (+3.20%)
Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvessâ„¢ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics

HUMA : 1.3200 (+10.92%)
Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvessâ„¢ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025

HUMA : 1.3200 (+10.92%)
Humacyte to Present at the TD Cowen 45th Annual Health Care Conference

HUMA : 1.3200 (+10.92%)

Business Summary

Humacyte Inc. is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale. Humacyte Inc., formerly known as Alpha Healthcare Acquisition Corp., is based in DURHAM, N.C.

See More

Key Turning Points

3rd Resistance Point 1.4833
2nd Resistance Point 1.4067
1st Resistance Point 1.3633
Last Price 1.3200
1st Support Level 1.2433
2nd Support Level 1.1667
3rd Support Level 1.1233

See More

52-Week High 9.9700
Fibonacci 61.8% 6.6008
Fibonacci 50% 5.5600
Fibonacci 38.2% 4.5192
Last Price 1.3200
52-Week Low 1.1500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar